AccessibilityHelpAbout Us
Sino Biopharmaceutical logo

Sino Biopharmaceutical(OTC) SBHMY

Market Cap$13.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)+94%
5 Year-5%
1 Year-25%
1 Month+14%
$14.50
-0.69%
-0.10Today
Sino Biopharmaceutical last closing stock price
MetricPriceDate
Last closeUSD 14.602026-09-24
Sino Biopharmaceutical stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.39%USD 14.542026-09-17
1 month+13.78%USD 12.832026-08-24
3 month+17.93%USD 12.382026-06-26
Year to date-17.93%USD 17.792025-12-31
1 year-25.35%USD 19.562025-09-24
3 year+116.59%USD 6.742023-09-22
5 year-4.76%USD 15.332021-09-22
Since inception+94.04%USD 7.522017-09-05

Sino Biopharmaceutical Financials at a Glance

Market Cap

$13.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CN¥33.70B

Net Income (TTM)

CN¥2.39B

EPS (TTM)

$0.39

P/E Ratio

37.20

Dividend

$0.31

Beta (Volatility)

0.06 (Low)

Price

$14.50

Volume

2,000

Open

$14.50

Previous Close

$14.60

Daily Range

$14.50 - $14.50

52-Week Range

$11.27 - $20.16

Estimated Earnings Date

Mar 18, 2026

SBHMY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Sino Biopharmaceutical

Sino Biopharmaceutical Limited is a leading research and development-focused pharmaceutical company based in the People's Republic of China. The company operates through three main divisions, offering a diverse range of products across various therapeutic categories.

Products and Services
  • Oncology treatments, including Qingkeshu tablets and Leweixin injections
  • Cardiovascular and cerebrovascular medications like Kaina and Anrixin tablets
  • Advanced pharmaceutical agents such as Aprepitant and Lenvatinib Mesilate
Growth Outlook
  • Revenue of CNY 9.72 billion in Q2 2026, indicating strong market demand
  • Net income of CNY 1.72 billion for Q2 2026, showcasing profitability
  • Consistent investment in R&D, with CNY 1.54 billion allocated in Q2 2026
Financial Highlights
  • Trailing twelve-month revenue of CNY 36.5 billion, reflecting robust growth
  • Net profit margin of 7.09% for the trailing twelve months, indicating operational efficiency
  • Dividend yield of 2.17%, providing a return to shareholders
Sino Biopharmaceutical Limited has established itself as a significant player in the pharmaceutical industry, particularly in China. The company's extensive product portfolio addresses critical health issues, including oncology and cardiovascular diseases. Recent financial performance highlights a strong revenue stream and profitability, supported by substantial investments in research and development. The company's commitment to innovation and quality positions it well for future growth, making it an intriguing option for potential investors.
AI Generated • Sep 18, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

21,435

CEO

S Y Tse

Website

www.sinobiopharm.com

Headquarters

Hong Kong, HK

SBHMY Financials

Key Financial Metrics (TTM)

Gross Margin

82.43%

Operating Margin

29.76%

Net Income Margin

7.09%

Return on Equity

7.56%

Return on Capital

14.17%

Return on Assets

2.87%

Earnings Yield

2.69%

Dividend Yield

2.10%

Payout Ratio

62.89%

Stock Overview

Market Cap

$13.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

890.72M

Volume

2.00K

Avg. Volume

74.938

Financials (TTM)

Gross Profit

CN¥27.78B

Operating Income

CN¥10.03B

EBITDA

CN¥10.41B

Operating Cash Flow

CN¥6.13B

Capital Expenditure

-CN¥967.92M

Free Cash Flow

CN¥5.16B

Cash & ST Invst.

CN¥27.58B

Total Debt

CN¥17.17B

Sino Biopharmaceutical Performance Analysis

Sino Biopharmaceutical annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CNY 3,865,044,535-7.2%
20232023-12-31CNY 3,697,861,481-4.3%
20242024-12-31CNY 4,010,960,7448.5%
20252025-12-31CNY 4,428,560,97610.4%
Sino Biopharmaceutical sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-18.9%
Q42025-12-31N/A
Q12026-03-3136.4%
Q22026-06-30N/A
Sino Biopharmaceutical annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CNY 0.36-84.1%
20232023-12-31CNY 0.36-1.6%
20242024-12-31CNY 0.27-23.5%
20252025-12-31CNY 0.3632.8%
Sino Biopharmaceutical sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-130.9%
Q42025-12-31N/A
Q12026-03-31427.9%
Q22026-06-30N/A

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

CN¥9.72B

+10.6%

Gross Profit

CN¥8.07B

+11.4%

Gross Margin

83.05%

N/A

Market Cap

$13.00BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$606.69K

N/A

Employees

21,435

N/A

Net Income

CN¥1.72B

+1.4%

EBITDA

CN¥3.55B

+79.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

CN¥27.58B

+39.1%

Total Debt

CN¥17.17B

+43.6%

Accounts Receivable

CN¥10.68B

+30.9%

Inventory

CN¥1.97B

-6.4%

Long Term Debt

CN¥8.49B

+175.4%

Short Term Debt

CN¥8.68B

-2.2%

Return on Assets

2.87%

N/A

Return on Invested Capital

17.85%

N/A

Free Cash Flow

CN¥0.00

-100.0%

Operating Cash Flow

CN¥0.00

-100.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SAUHFStraumann Holding AG
$112.60-2.10%
SAUHYStraumann Holding AG
$11.76+1.20%
GNMSFGenmab A/S
$346.76+2.36%
IVBXFInnovent Biologics, Inc.
$12.45-0.78%

Trending Stocks

Symbol / CompanyPricePrice Chg
GLNDGreenland Energy
$5.85+9.35%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.93-3.17%
INTCIntel
$124.75-2.07%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$32.08-4.61%

Questions About SBHMY

What is the current price of Sino Biopharmaceutical?

Sino Biopharmaceutical is trading at $14.50 per share.

What is the 52-week range for Sino Biopharmaceutical?

Over the past 52 weeks, Sino Biopharmaceutical has traded between $11.27 and $20.16.

How much debt does Sino Biopharmaceutical have?

As of the most recent reporting period, Sino Biopharmaceutical reported total debt of CN¥2.30B.

How much cash does Sino Biopharmaceutical have on hand?

Sino Biopharmaceutical reported CN¥1.06B in cash and cash equivalents in its most recent financial results.

What is Sino Biopharmaceutical’s dividend yield?

Sino Biopharmaceutical currently has a dividend yield of 2.10%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services